Factors affecting time required to reach maintenance dose during subcutaneous immunotherapy

International Forum of Allergy and Rhinology

Volumn 2, Issue 4, 2012, Pages 294-299

  Jourdy, Deya N ^a   Reisacher, William R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Allergen immunotherapy; Conventional protocol; Maintenance dose; Specific hyposensitization; Subcutaneous immunotherapy; Time

Indexed keywords

ALLERGEN; STEROID;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; POLYPOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHINORRHEA; RHINOSINUSITIS; SCHOOL CHILD; SEX DIFFERENCE; SMOKING; SUBCUTANEOUS IMMUNOTHERAPY; TIME; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; ASTHMA; CHILD; DESENSITIZATION, IMMUNOLOGIC; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84864794993     PISSN: 20426976     EISSN: 20426984     Source Type: Journal    
DOI: 10.1002/alr.21027     Document Type: Article

References (28)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1-S84.
2. Lund VL, Aaronson D, Bousquet J, et al. International consensus report on the diagnosis and management of rhinitis. Allergy. 1994;49(Suppl 19):1-34.
3. Malling HJ. [Allergen-specific immune therapy in the treatment of asthma.] Ugeskr Laeger. 2000;162:477-479. [Danish]
4. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562.
5. Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. BMJ. 1993;307:919-923.
6. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025-1034.
7. Passalacqua G, Durham SR; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol. 2007;119:881-891.
8. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001936.
9. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):CD001186.
10. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97:126-137.
11. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969-974.
12. Cox LS. Shooting for a faster approach to the immunotherapy target: will cluster become conventional? Ann Allergy Asthma Immunol. 2009;102:177-178.
13. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol. 1993;91:734-737.
14. Pfaar O, Leitzbach S, Hörmann K, Klimek L. Cluster protocols in SCIT: enough evidence for practical use? Curr Opin Allergy Clin Immunol. 2010;10:188-193.
15. Freeman J. "Rush" inoculation, with special reference to hay-fever treatment. Lancet. 1930;215:744-747.
16. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E; EAACI, Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1-3.
17. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy. 1993;70(6):480-482.
18. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003;(2):CD002893.
19. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021-1035.
20. Robinson DS. The role of the T cell in asthma. J Allergy Clin Immunol. 2010;126:1081-1091; quiz 1092-1083.
21. Pfaar O, Hörmann K, Klimek L. [Cluster-immunotherapy in allergic rhinoconjunctivitis: a review of an innovative, new therapeutic approach.] Die Cluster-immuntherapie bei allergischer rhinokonjunktivitis: Übersicht über ein innovatives Therapiekonzept. Allergo J. 2009;32:433-440. [German]
22. Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 1992;90(4 Pt 1):567-578.
23. Tabar AI, Echechipía S, García BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116:109-118.
24. Casanovas M, Martín R, Jiménez C, Caballero R, Fernández-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol. 2006;139:153-158.
25. Pfaar O, Mösges R, Hörmann K, Klimek L. Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2010;267:245-250.
26. Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148:251-260.
27. Serrano P, Justicia JL, Sánchez C, et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol. 2009;102:247-252.
28. Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J. Comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol. 2009;148:161-169.